Northern Trust Corp Makes New Investment in TuHURA Biosciences (NASDAQ:HURA)

Northern Trust Corp purchased a new stake in TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 57,248 shares of the company’s stock, valued at approximately $234,000. Northern Trust Corp owned 0.14% of TuHURA Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the 4th quarter valued at $29,000. TT Capital Management LLC bought a new stake in TuHURA Biosciences in the fourth quarter valued at $41,000. Charles Schwab Investment Management Inc. bought a new stake in TuHURA Biosciences in the fourth quarter valued at $61,000. Hurlow Wealth Management Group Inc. acquired a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $170,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $253,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Stock Performance

Shares of HURA stock opened at $3.12 on Tuesday. The firm has a fifty day simple moving average of $3.71 and a two-hundred day simple moving average of $3.94. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of TuHURA Biosciences in a research note on Friday, May 16th.

TuHURA Biosciences Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.